NIOX GROUP PLC
("NIOX" or the "Company" and, together with its subsidiaries, the "Group")
AGM Statement
Oxford, UK - 22 May 2024: NIOX Group plc (AIM: NIOX), a medical device company focused on point of care asthma diagnosis and management, is holding its Annual General Meeting today at the Hayakawa Building, Edmund Halley Road, Oxford Science Park. Oxford OX4 4GB.
Trading Update
We are pleased to report that our business has continued to perform strongly in the year to date, in line with management expectations.
In January 2024, NIOX settled returns claims amounting to £0.4m in relation to the discontinued business. The unaudited cash balance as at 30 April 2024 was £23.7m (31 December 2023: £19.9m), with no bank borrowings.
NIOX expects to give a trading update in relation to the six months ended 30 June 2024 around the middle of July.
Contacts:
|
NIOX Ian Johnson, Executive Chairman Michael Roller, Chief Financial Officer |
Tel: +44 (0) 1865 405 560 |
|
Singer Capital Markets (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer / James Todd |
Tel: +44 (0) 20 7496 3000 |
|
Investec Bank plc (Joint Broker) Edward Knight / Bruce Garrow / Lydia Zychowska |
Tel: +44 (0) 20 7597 4000 |
About NIOX
Our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies.
NIOX provides products and services via its direct sales organisation and extensive distributor network in 50 countries. For more information, please visit www.niox.com